Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | CTSB | P07858 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445475 | 1.00 | CYP1A2 (0.71) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL781659 | 0.86 | CYP1A2 (0.87) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL12124658 | 0.86 | CYP1A2 (0.71) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL14377392 | 0.86 | CYP1A2 (0.71) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL3436165 | 0.86 | ALDH1A1 (0.74) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL22587515 | 0.85 | CYP1A2 (0.66) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL3280808 | 0.84 | CYP1A2 (0.69) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL12639914 | 0.84 | ALDH1A1 (0.72) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL18951797 | 0.83 | CYP1A2 (0.68) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL6708175 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848591-B | HDAC inhibitors and methods of making and using the same | 成都先导药物开发股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-111848591-A | HDAC inhibitors and methods of making and using the same | 成都先导药物开发股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020216298-A1 | HDAC INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都先导药物开发股份有限公司 | 2020-10-29 | — | — | WO | disclosed |
| EP-2228364-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | CYP1A2 707/4885CYP2C9 1065/4885CYP2C19 745/4885 |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | STS, SERPINB1, MPO | CYP1A2 300/4885CYP2C9 684/4885CYP2C19 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.